Prevalence and severity of urogenital symptoms in postmenopausal women receiving endocrine therapy for breast cancer

Clinical Breast Cancer

Volumn 9, Issue 2, 2009, Pages 108-117

  Chin, Sheray N ^a   Trinkaus, Mateya ^a   Simmons, Christine ^a   Flynn, Candi ^a   Dranitsaris, George ^b   Bolivar, Robyn ^a   Clemons, Mark ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anastrozole; Aromatase inhibitor; Sexual activity questionnaire; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; EXEMESTANE; LETROZOLE; PLACEBO; POLYCARBOPHIL; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; BURNING SENSATION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPAREUNIA; DYSURIA; FATIGUE; FEMALE; GENITAL PRURITUS; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SIDE EFFECT; SINGLE BLIND PROCEDURE; STRESS INCONTINENCE; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINARY URGENCY; URINE INCONTINENCE; UROGENITAL TRACT DISEASE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA SECRETION; VAGINAL DRYNESS; VULVOVAGINAL DISEASE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; HOSPITALIZATION; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 67649786817     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.020     Document Type: Article

References (32)

1. Ganz PA. Menopause and breast cancer: symptoms, late effects, and their management. Semin Oncol 2001; 28:274-83.
2. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002; 73:45-59.
3. The ATAC ('Arimidex', Tamoxifen Alone or in Combination) Trialists' Group. Anastrazole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359:2131-9.
4. Goss P, Ingle J, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 2003; 349:1793-802.
5. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-75.
6. Coombs RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-92.
7. Mourisden H, Gershanovish M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-606.
8. Naboholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimedex Study Group. J Clin Oncol 2000; 18:3758-67.
9. Smith IE, Dowsett M. Aromatase Inhibitors in Breast Cancer. N Engl J Med 2003; 348:2431-42.
10. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J Clin Oncol 2001; 19:3817-27
11. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet 1996; 348:1189-96.
12. Huirne JA, Lambalk CB. Gonadotropin-releasing hormone receptor antagonists. Lancet 2001; 358:1793-803.
13. Trinkaus M, Chin S, Wolfman W, et al. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008; 13:222-31.
14. Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women's health related quality of life and sexual functioning. J Clin Oncol 1998; 16:501-14.
15. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997; 314:228-31.
16. Mortimer JE, Boucher L, Baty J, et al. Effect of tamoxifen on sexual functioning in patients with breast cancer. J Clin Oncol 1999; 17:1488-92.
17. Day R, Ganz PA, Costantino J P, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999; 17:2659-69.
18. Gupta P, Sturdee DW, Palin SL, et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life. Climacteric 2006; 9:49-58.
19. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004; 15:753-60.
20. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352:93-7.
21. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet 1998; 352:98-101.
22. Dent S, Di Valentin T, Vandermeer L, et al. Toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center. Presented at: the 2006 San Antonio Breast Cancery Symposium; Abstract 4057.
23. Fallowfield LJ, Leaity SK, Howell A, et al. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine system subscale for the FACT-B. Breast Cancer Res Treat 1999; 55:189-99.
24. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity Questionnaire: a measure of women's sexual functioning. Qual Life Res 1996; 5:81-90.
25. Cella D, Fallowfied L, Barker P, et al; On behalf of the ATAC Trialists Group. Quality of life of postmenopausal women in the ATAC ("Arimidex" , Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006; 100:273-84.
26. Fallowfield L, Cella D, Cuzick J, et al. Quality of Life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004; 22:4261-71.
27. Mourits MJ, Böckermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomized breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 2002; 86:1546-50.
28. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994; 61:178-80.
29. Eriksen BC. A randomized, open, parallel-group study on the preventive effect of estradiol-releasing vaginal ring on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999; 180:1072-9.
30. Dessole I, Rubattu G, Ambrosini G. Efficacy of low dose intravaginal estriol on urogenital aging in post menopausal women. Menopause 2004; 11:49-56.
31. Suckling J, Lethaby A, Kennedy R. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; (4):CD001500.
32. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94:606-16.